Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1605 studies found for:    "B-cell lymphomas"
Show Display Options
Rank Status Study
1 Completed Treatment of Mature B-cell Lymphoma/Leukaemia
Condition: B-Cell Lymphoma
Interventions: Drug: half cyclophosphamide;   Drug: without COPADM3;   Drug: mini CYVE, without 3 maintenance courses;   Drug: LMB B;   Drug: LMB C
2 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
3 Active, not recruiting Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Condition: B-cell Lymphoma
Interventions: Drug: SD-101;   Radiation: Radiation therapy
4 Recruiting A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Condition: B-Cell Lymphoma
Intervention: Drug: CPI-1205
5 Completed An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Condition: B-cell Lymphoma
Intervention: Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
6 Completed Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
Condition: B-Cell Lymphomas
7 Recruiting Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
Condition: B-cell Lymphomas
Intervention: Genetic: Anti-CD19 CAR T cells
8 Completed Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
Condition: B-cell Lymphomas
Intervention: Drug: Oxaliplatin, Prednisolone
9 Completed A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
Condition: Primary Mediastinal B-Cell Lymphoma
10 Recruiting Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Condition: Marginal Zone B-cell Lymphoma
Intervention: Drug: bendamustine plus rituximab
11 Unknown  High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
Condition: B-Cell Lymphomas
Intervention: Drug: High-dose sequential chemotherapy and autologous transplant
12 Completed High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Drug: 90Y-ibritumomab
13 Recruiting CD19-targeting CAR T Cells for B Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Biological: CD19-targeting CAR T Cells infusion
14 Completed High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
Condition: B-Cell Lymphoma
Intervention: Drug: Rituximab
15 Active, not recruiting Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
16 Completed Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma
Condition: Diffuse Large B-cell Lymphoma
Intervention: Other: EBER
17 Unknown  Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Drug: Rituximab -CHOP plus Velcade
18 Unknown  Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Gemcitabine;   Drug: Methylprednisolone;   Drug: Rituximab;   Drug: Cisplatin;   Drug: Lenalidomide
19 Recruiting The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Condition: B Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19
20 Recruiting Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Biological: autologous anti-CD19 CAR T cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.